美国退伍军人新发射血分数降低心衰的医疗质量评估
结果显示药物治疗率仅有小幅改善,2019年指南推荐β受体阻滞剂使用率为72.0%,血管紧张素受体脑啡肽酶抑制剂仅为22.6%,风险调整死亡率从19.9%降至18.4%。
要点
- 指南推荐β受体阻滞剂使用率从2013年64.2%升至2019年72.0%,改善有限。
- 血管紧张素受体脑啡肽酶抑制剂2019年使用率仅22.6%,盐皮质激素受体拮抗剂为26.9%。
- 风险调整死亡率从19.9%降至18.4%,每年OR为0.96(95%CI 0.96-0.97)。
核心结论
- 2013至2019年间新发射血分数降低心衰患者的指南推荐治疗率和死亡率仅有边际改善。
- 亟需新方法提高循证治疗采用率以进一步降低死亡率。
研究设计与样本
- 这项队列研究分析2013年7月1日至2019年6月30日美国退伍军人事务部医疗系统内新发射血分数降低心衰患者的理赔和电子健康记录数据。
- 排除有心脏移植史或使用心室辅助装置的患者。
主要发现
- 指南推荐β受体阻滞剂使用率从2013年64.2%升至2019年72.0%。
- 盐皮质激素受体拮抗剂使用率从2013年23.9%升至2019年26.9%,肼屈嗪加硝酸酯类使用率稳定在24.2%。
- 血管紧张素受体脑啡肽酶抑制剂自2015年引入后使用率上升,但2019年仅达22.6%。
- 在有ICD指征的患者中,早期使用率随时间下降。
- 风险调整死亡率从2013-2015年的19.9%(95%CI 19.6%-20.2%)降至2017-2019年的18.4%(95%CI 18.0%-18.7%),每年OR为0.96(95%CI 0.96-0.97)。
关键数值与推荐
- 指南推荐β受体阻滞剂包括比索洛尔、卡维地洛或琥珀酸美托洛尔。
- 指南导向药物治疗包括任何β受体阻滞剂、指南推荐β受体阻滞剂、ACEI、ARB、ARNI、MRA及肼屈嗪加硝酸酯类。
- 治疗率在指数HFrEF日期后6个月内通过药物填充、手术编码和诊断编码计算。
临床怎么用
- 临床应关注新发射血分数降低心衰患者对指南推荐药物的早期启用和滴定。
- 需识别并解决治疗率在不同医疗设施间的显著差异。
- 应重视ICD在有指征患者中的早期使用率下降趋势。
局限性
- 研究基于退伍军人事务部医疗系统数据,结果可能受限于该人群特征(主要为老年男性)。
- 使用理赔和电子健康记录数据可能受编码准确性影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Multiple guideline-recommended therapies for heart failure with reduced ejection fraction (HFrEF) are available and promoted by performance measures. However, contemporary data on the use of these therapies are limited. OBJECTIVE: To evaluate trends in guideline-directed medical therapy, implantable cardioverter-defibrillator (ICD) use, and risk-adjusted mortality among patients with recent-onset HFrEF. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed claims and electronic health record data of patients with recent-onset HFrEF diagnosed at US Department of Veterans Affairs (VA) health care system facilities from July 1, 2013, through June 30, 2019. Veterans who had a history of heart transplant or used a ventricular assist device were among the patients who were excluded. EXPOSURES: Guideline-directed medical therapy (any β-blocker, guideline-recommended β-blocker [bisoprolol, carvedilol, or metoprolol succinate], angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, angiotensin receptor-neprilysin inhibitor, mineralocorticoid receptor antagonist, and hydralazine plus nitrate) and ICD. MAIN OUTCOMES AND MEASURES: Treatment rates for guideline-directed medical therapies and ICDs were calculated within 6 months of the index HFrEF date using medication fills, procedural codes for implantation and monitoring, and diagnosis codes. Risk-adjusted mortality was calculated after adjusting for baseline patient characteristics. For both treatment rates and risk-adjusted mortality, we evaluated the change over 3 periods (period 1: July 1, 2013, to June 30, 2015; period 2: July 1, 2015, to June 30, 2017; and period 3: July 1, 2017, to June 30, 2019) and variation across VA facilities. RESULTS: The final cohort comprised 144 074 eligible patients with incident HFrEF that was diagnosed between July 1, 2013, and June 30, 2019. The cohort had a mean (SD) age of 71.0 (11.4) years and was mostly composed of men (140 765 [97.7%]). Overall, changes in medical therapy rates were minimal over time, with the use of a guideline-recommended β-blocker increasing from 64.2% in 2013 to 72.0% in 2019. Rates for mineralocorticoid receptor antagonist therapy increased from 23.9% in 2013 to 26.9% in 2019, and rates for hydralazine plus nitrate therapy remained stable at 24.2% over the study period. Rates for angiotensin receptor-neprilysin inhibitor therapy increased since its introduction in 2015 but only to 22.6% in 2019. Among patients with an ICD indication, early use rates decreased over time. Substantial variation in medical therapy rates persisted across VA facilities. Risk-adjusted mortality decreased over the study period from 19.9% (95% CI, 19.6%-20.2%) in July 1, 2013, to June 30, 2015, to 18.4% (95% CI, 18.0%-18.7%) in July 1, 2017, to June 30, 2019 (OR, 0.96 per additional year; 95% CI, 0.96-0.97). CONCLUSIONS AND RELEVANCE: This study found only marginal improvement between 2013 and 2019 in the guideline-recommended therapy and mortality rates among patients with recent-onset HFrEF. New approaches to increase the uptake of evidence-based HFrEF treatment are urgently needed and could lead to larger reductions in mortality.
引用
- Sandhu, Kohsaka, Turakhia, et al. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2022. PMID: 34757380. doi:10.1001/jamacardio.2021.4585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。